This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biotech Calendar: Key Dates for March

Stocks in this article: HGSI DNDN CTIC BMY ACHN CELG CORT

BOSTON, Mass. ( TheStreet) -- A calendar of important, potentially stock-moving biotech events for March:

March 7-9:
Cowen & Co. Annual Healthcare Conference

March 9-13:
National Comprehensive Cancer Network Annual Meeting (NCCN)

March 10:
Human Genome Sciences (HGSI): FDA drug approval decision date for Benlysta in lupus.
Dendreon (DNDN): FDA approval decision for expansion of Provenge manufacturing capacity at New Jersey facility.

March 18-22:
American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting.

March 24-27:
American Academy of Pain Medicine (AAPM) meeting.

March 26:
Bristol-Myers Squibb (BMY): FDA drug approval decision date for Yervoy in melanoma.

March 30 - April 3:
European Association for the Study of the Liver (EASL) annual meeting.

Other potential biotech events in March:

Cell Therapeutics (CTIC): Outcome of FDA appeal meeting for pixantrone in aggressive non-Hodgkin's lymphoma

A.P. Pharma (APPA): Meeting with FDA to discuss requirements for resubmission of APF530 for chemotherapy-induced nausea following last year's rejection letter.

Achillion Pharmaceuticals: (ACHN) Top-line results from 28-day, phase IIa study of hepatitis C drug ACH-1625.

Celgene (CELG): Top-line results from phase II study of amrubicin in small-cell lung cancer.

Corcept Therapeutics: (CORT) FDA approval filing for Corlux in Cushing's syndrome.

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs